
Effect of High-Dose Intravenous Immunoglobulin on Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy
Marinos C. Dalakas, MD;
Daniel P. Stein, MD;
Carlos Otero, MD;
Elizabeth Sekul, MD;
Edward J. Cupler, MD;
Susan McCrosky, RN
Arch Neurol. 1994;51(9):861-864.
Abstract
 |  |
Objective To determine if high-dose intravenous immunoglobulin therapy is effective in improving muscle strength or in arresting the pace of disease progression in patients with rapidly progressive amyotrophic lateral sclerosis.
Design An open-label pilot study of intravenous infusions of high-dose immunoglobulin administered once a month for 3 months in nine patients with classic amyotrophic lateral sclerosis. Selected patients had a rapidly progressive course with signs of worsening noticeably evident every 6 weeks prior to therapy. A patient with multifocal motor neuropathy with conduction block that presented as a lower motor neuron syndrome was concurrently treated to document the efficacy of the same preparation of immunoglobulin in a potentially treatable disease that simulates lower motor neuron syndrome. The efficacy of high-dose intravenous immunoglobulin infusions was assessed by objective measurement of maximum voluntary isometric contraction in all muscle groups of two limbs before and after therapy.
Setting The Clinical Center of the National Institutes of Health, Bethesda, Md.
Results All patients with amyotrophic lateral sclerosis worsened during the study. By the end of the third month, their mean total muscle scores (megascores) had declined by 71.2 points, from a mean of 369.7 (range, 200 to 605) to 298.5 (range, 130 to 552) points. The pace of progression did not change during the 4-month observation period. In contrast, the patient with multifocal motor neuropathy responded to intravenous immunoglobulin therapy and increased his megascores by 146 points after 3 months. The GM1 antibody titers were normal in all the patients.
Conclusions High-dose intravenous immunoglobulin, a prohibitively expensive drug, has no apparent therapeutic role in improving the symptoms or arresting the pace of progression in patients with amyotrophic lateral sclerosis. In contrast, multifocal motor neuropathy is an immunopathologically different disease that responds to intravenous immunoglobulin therapy.
Author Affiliations
From the Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test.
Nodera et al.
Neurology 2006;67:280-287.
ABSTRACT
| FULL TEXT
Axon loss is an important determinant of weakness in multifocal motor neuropathy.
Van Asseldonk et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:743-747.
ABSTRACT
| FULL TEXT
Seroconversion of anti-GM1 antibodies in patients with amyotrophic lateral sclerosis
Haggiag et al.
Neurology 2004;63:755-756.
FULL TEXT
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
Dalakas
JAMA 2004;291:2367-2375.
ABSTRACT
| FULL TEXT
Intravenous immunoglobulin in neurological disease: a specialist review
Wiles et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:440-448.
ABSTRACT
| FULL TEXT
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No
Karussis and Abramsky
Arch Neurol 1999;56:1028-1032.
FULL TEXT
|